For nearly a quarter of a century, frontline diffuse large B-cell lymphoma (DLBCL) has resisted every attempt at therapeutic reinvention.
Since the landmark GELA LNH 98-5 study established R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) in 2002, dozens of Phase 3 clinical trials have attempted to displace the regimen. Proteasome inhibitors, immunomodulatory agents, and BTK inhibitors all fell short in broad, unselected patient populations. Even modern antibody-drug conjugates like Roche’s Polivy (polatuzumab vedotin + R-CHP) managed only an incremental 27% reduction in progression risk without demonstrating an overall survival benefit.
On October 5, 2026, that 24-year plateau broke.
AbbVie and Genmab announced headline results from their pivotal Phase 3 EPCORE DLBCL-2 trial (NCT04663347). The combination of subcutaneous epcoritamab (Epkinly / DuoBody-CD3xCD20) with standard R-CHOP demonstrated a statistically significant and clinically decisive 51% reduction in the risk of disease progression or death (Hazard Ratio: 0.49; p < 0.0001) compared to R-CHOP alone in previously untreated patients with high-risk DLBCL (IPI 2–5).
Cracking the R-CHOP Plateau #
Diffuse large B-cell lymphoma is the most common form of non-Hodgkin lymphoma worldwide, accounting for roughly 30% to 40% of all newly diagnosed lymphoma cases. While R-CHOP cures roughly 60% of patients, the remaining 40% experience refractory disease or early relapse—trapping patients in a high-mortality cycle requiring salvage high-dose chemotherapy, autologous stem cell transplantation, or costly CAR-T cell infusions.
The EPCORE DLBCL-2 trial enrolled over 900 treatment-naïve patients globally, evaluating whether incorporating a full-length, IgG1-bispecific antibody could eradicate minimal residual disease (MRD) during initial induction therapy.
The resulting hazard ratio of 0.49 represents the largest relative risk reduction ever documented in a randomized frontline clinical trial for aggressive B-cell lymphoma.
The Subcutaneous Pharmacokinetic Buffer #
The central technological breakthrough enabling epcoritamab's frontline success is its delivery route and structural engineering.
Historically, systemic administration of T-cell engaging bispecific antibodies was plagued by severe, life-threatening Cytokine Release Syndrome (CRS). Intravenous infusions create sharp, rapid peak serum concentrations (Cmax) that provoke massive systemic interleukin-6 (IL-6) and interferon-gamma release from circulating lymphocytes.
Epcoritamab is formulated for subcutaneous injection. Subcutaneous administration routes the antibody through the lymphatic drainage network, extending absorption time (Tmax ~3 to 4 days) and buffering against severe cytokine spikes.
Paired with a mandatory Cycle 1 step-up dosing protocol (0.16 mg on Day 1, 0.8 mg on Day 8, and full 48 mg dosing on Day 15), the rate of severe Grade 3 or higher CRS in EPCORE DLBCL-2 remained below 2.5%, allowing the vast majority of patients to be managed safely in outpatient community settings.
The Obligate Cytolytic Synapse #
At the molecular level, epcoritamab utilizes Genmab’s DuoBody technology platform, incorporating matched point mutations (F405L and K409R) alongside silenced Fc domains that prevent non-specific Fc-gamma receptor binding.
When administered, epcoritamab simultaneously cross-links:
- CD20 expressed broadly on malignant lymphoma B-cells.
- CD3ε within the T-cell receptor complex on endogenous cytotoxic CD8+ T-lymphocytes.
This dual engagement forces the formation of an obligate cytolytic immune synapse. By compressing the intermembrane spacing between the effector T-cell and the lymphoma cell to roughly 15 nanometers, large inhibitory surface phosphatases such as CD45 are physically excluded from the junction.
The resulting signal triggers polarized, directional release of perforin and granzyme-B directly into the lymphoma membrane, driving apoptotic DNA cleavage independent of major histocompatibility complex (MHC) presentation.
The Commercial Challenge to Roche's Polivy #
The readout delivers an immediate commercial challenge to Roche.
Roche spent significant commercial capital establishing Polivy (polatuzumab vedotin + R-CHP) as the frontline alternative to R-CHOP following the POLARIX trial. However, Polivy's modest hazard ratio of 0.73 and lack of proven overall survival separation left many hematologists hesitant to adopt the added cost and peripheral neuropathy risks.
With an HR of 0.49 and a clean neurotoxicity profile, AbbVie and Genmab have established an overwhelmingly compelling clinical argument for epcoritamab as the new worldwide standard of care.
AbbVie and Genmab indicated that global regulatory submissions to the US FDA and the European Medicines Agency (EMA) will commence immediately, with full detailed subgroup analyses scheduled for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting.
